Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.36 SEK | +0.56% | +8.76% | +10.09% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.09% | 7.38M | - | ||
-20.45% | 10.82B | A- | ||
+43.17% | 3.25B | D+ | ||
-35.86% | 2.11B | C | ||
-17.21% | 2.08B | - | B- | |
-29.81% | 1.48B | C+ | ||
+17.56% | 1.02B | B- | ||
-4.37% | 733M | C+ | ||
-37.00% | 391M | C- | ||
-46.94% | 377M | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- SPAG Stock
- Ratings Spago Nanomedical AB